A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Clinical Trial

— AADC  

Official title:

A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01395641
• Other study ID #: NTUH-AADC-010(200802042M)
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 22, 2014
• Est. completion date: March 7, 2022

Study information

• Verified date: November 2022
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase I/II trial is to prove the efficacy and safety of AAV2-hAADC to treat patients with AADC deficiency.

Description:

Aromatic L-amino acid decarboxylase (AADC) is an enzyme responsible for the final step in the synthesis of neurotransmitters dopamine and serotonin. AADC deficiency is a rare genetic disorder. Taiwanese carry a high prevalence of AADC deficiency due to the founder mutation IVS6+4 A>T, and patients usually die before the age 5-6 years due to severe motor dysfunction.

Gene therapy with adeno-associated virus (AAV) serotype 2 (AAV2) driven human AADC (hAADC) has been tested in both animal models and Phase I clinical trials of Parkinson disease. We have done a compassionate treatment of 8 patients with AADC deficiency by AAV2-hAADC and demonstrated a result that among the treated patients, 4 could stand with support, 3 could sit with support, and there was no virus-associated toxicity. The longest follow up has exceeded 4 years.

This study is to prove the safety and efficacy of AAV2-hAADC treatment for patients with Aromatic L-amino acid decarboxylase (AADC) deficiency.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 7, 2022
• Est. primary completion date: December 18, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Months and older

Eligibility

Inclusion Criteria:

1. With a confirmed diagnosis of AADC, including cerebrospinal fluid analysis to show reduced levels of neurotransmitter metabolites, HVA and 5-HIAA, and higher L-Dopa, together with more than one mutation within AADC gene.

2. Classical clinical characteristics of AADC deficiency, such as oculogyric crises, hypotonia and developmental retardation.

3. The sick child has to be over 2 years old or a head circumference big enough for surgery.

4. Participating patients must cooperate completely for all evaluations and examinations before, during and after the whole trial.

5. Parents or guardians must sign to agree on this informed consent.

Exclusion criteria

1. Significant brain structure abnormality

2. Patients with any health or neurological doubts that may increase the risk of surgery cannot join this trial. PI has the right to evaluate the feasibility of subjects for this trial based on his/her health condition.

3. Since high-level neutralizing antibodies may disturb the therapeutic effect of gene therapy, patients with anti-AAV2 neutralizing antibody titer over 1,200 folds or an ELISA OD over 1 cannot be enrolled into this trial.

4. Subjects enrolled in this clinical trial cannot take any medications that may affect this trial.

Related Conditions & MeSH terms

• Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Intervention

Drug:
• gene therapy
AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
National Taiwan University Hospital	PTC Therapeutics

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of therapeutic effect	At one year post-surgery, neurotransmitter metabolites (HVA or HIAA) is detectable in CSF (higher than that at pre-surgery); At one year post-surgery, PDMS-II score is higher than that at pre-surgery, with an improvement over 10 points	12 months
Secondary	Evaluation of safety and other therapeutic effects Evaluation for the treatment safety	The absence of intracranial bleeding, which requires surgical management, after the surgery; Craniotomy-induced CSF exudation; The severity of post-surgery hyperactivity (if feeding is affected and then nasogastric tube is needed); Incidence of other severe adverse events (information of adverse events of all kinds and severities will be collected, including treatment-emergent adverse events).	12 months
Secondary	Evaluation of secondary therapeutic effects	Weight gain; Increased signal intensity of dopamine in putamen during PET imaging; Increased score in other development evaluations	5 years
Secondary	Exploratory endpoint	The correlation between anti-AAV2 titer and therapeutic effect; The correlation between subject's age and therapeutic effect	5 years